<unk> , sold under the brand name Zydelig, is a medication used to treat certain blood cancers. The substance acts as a phosphoinositide 3-kinase inhibitor; more specifically, it blocks P110δ, the delta isoform of the enzyme phosphoinositide 3-kinase. It was developed by Gilead Sciences.<unk>  had annual sales of $168 million (USD) during the year of 2016, up from $132 million (USD) in 2015.
Idelalisib
Duvelisib
Alpelisib
Etalocib
Glasdegib
Enasidenib
Vismodegib
Ivosidenib